ChromaDex appoints Caroline S. Levy to Board, effective December 1, 2021

Niagen Bioscience, Inc.

Caroline S. Levy, former Senior Equity Research Analyst at Macquarie Capital, joins ChromaDex Board.
Ms. Levy appointed to Audit Committee and Nominating and Corporate Governance Committee.
Annual retainer of $40,000, plus $10,000 (Audit) and $5,000 (Nominating) committee fees.
Granted option to purchase 40,000 shares vesting over three years; annual meeting options of 20,000 shares.
Board determined Ms. Levy is independent under Nasdaq rules.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Caroline S. Levy

Director

NAGE · Niagen Bioscience, Inc.

Effective: 2021-12-01
Filed: December 1, 2021, 6:59 PM ET

On December 1, 2021, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) appointed Caroline S. Levy as a member of the Board effective on such date, to serve until the Company’s 2022 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Caroline S. Levy was appointed as Director at Niagen Bioscience, Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 1, 2021, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) appointed Caroline S. Levy as a member of the Board effective on such date, to serve until the Company’s 2022 annual meeting of stockholders.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-21-024319

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.